Amneal Pharmaceuticals received approval for its abbreviated new drug application for the drug in six strengths — 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg — according to a Feb. 19 news release from the drugmaker.
Some common adverse reactions associated with the drug, which is used to treat certain blood cancers, include neutropenia, thrombocytopenia and leukopenia.
